• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性阻塞性肺疾病(COPD)根据GOLD和STAR严重程度分期的死亡率及急性加重风险:一项为期5年的多中心前瞻性队列研究

Mortality and exacerbation risk according to GOLD and STAR severity stages of COPD: a 5-year multicenter prospective cohort study.

作者信息

Ogata Hiroaki, Tsubouchi Kazuya, Takano Tomotsugu, Ichiki Katsuyuki, Torii Ryo, Takata Shohei, Nakagaki Noriaki, Yoshida Makoto, Kitasato Yasuhiko, Tobino Kazunori, Harada Eiji, Wataya Hiroshi, Ishii Hiroshi, Maeyama Takashige, Kawasaki Masayuki, Fujita Masaki, Yatera Kazuhiro, Zaizen Yoshiaki, Nakanishi Yoichi, Okamoto Isamu

机构信息

Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.

Kirigaoka Tsuda Hospital, Kitakyushu, Japan.

出版信息

Sci Rep. 2025 May 30;15(1):19097. doi: 10.1038/s41598-025-05033-w.

DOI:10.1038/s41598-025-05033-w
PMID:40447720
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12125300/
Abstract

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification, based on percent predicted forced expiratory volume in 1 s (ppFEV1), has been widely adopted for assessment of chronic obstructive pulmonary disease (COPD) severity. However, the STaging of Airflow obstruction by Ratio (STAR) system, based on the ratio of FEV1 to forced vital capacity, was recently proposed as an alternative classification. This study aimed to compare the prognostic performance of the GOLD and STAR classifications for prediction of mortality and exacerbation risk in individuals with COPD. This 5-year prospective, multicenter cohort study enrolled 370 individuals with COPD at 29 medical centers. All-cause mortality risk across GOLD and STAR stages was evaluated with Kaplan-Meier curves and Cox proportional hazards models. The risk of moderate to severe COPD exacerbations across GOLD and STAR stages was examined with cumulative incidence function (CIF) curves and Fine and Gray models. Both classification systems showed a significant association with mortality and exacerbation risk (P < 0.01 for trend). The GOLD classification provided a better separation of Kaplan-Meier and CIF curves for advanced stages, whereas the STAR classification showed a clearer distinction between stages I and II. These associations remained consistent after multivariable adjustments. The GOLD classification was superior for prediction of prognosis in advanced COPD, whereas the STAR classification provided better differentiation in early-stage disease. These findings highlight the complementary roles of the GOLD and STAR classifications in assessment of COPD severity.

摘要

基于1秒用力呼气容积预测值百分比(ppFEV1)的慢性阻塞性肺疾病全球倡议(GOLD)分类已被广泛用于评估慢性阻塞性肺疾病(COPD)的严重程度。然而,最近有人提出基于FEV1与用力肺活量比值的气流阻塞分期(STAR)系统作为一种替代分类方法。本研究旨在比较GOLD和STAR分类对COPD患者死亡率和急性加重风险预测的预后性能。这项为期5年的前瞻性多中心队列研究在29个医疗中心招募了370例COPD患者。采用Kaplan-Meier曲线和Cox比例风险模型评估GOLD和STAR各阶段的全因死亡风险。采用累积发病率函数(CIF)曲线和Fine and Gray模型研究GOLD和STAR各阶段中重度COPD急性加重的风险。两种分类系统均与死亡率和急性加重风险显著相关(趋势P < 0.01)。GOLD分类在晚期阶段的Kaplan-Meier曲线和CIF曲线分离效果更好,而STAR分类在I期和II期之间的区分更明显。多变量调整后,这些关联仍然一致。GOLD分类在晚期COPD预后预测方面更优,而STAR分类在早期疾病中具有更好的区分度。这些发现突出了GOLD和STAR分类在评估COPD严重程度方面的互补作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca1b/12125300/3b3aa5f29d22/41598_2025_5033_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca1b/12125300/0b24db40a605/41598_2025_5033_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca1b/12125300/304d19d081c3/41598_2025_5033_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca1b/12125300/23e9b928449d/41598_2025_5033_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca1b/12125300/3b3aa5f29d22/41598_2025_5033_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca1b/12125300/0b24db40a605/41598_2025_5033_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca1b/12125300/304d19d081c3/41598_2025_5033_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca1b/12125300/23e9b928449d/41598_2025_5033_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca1b/12125300/3b3aa5f29d22/41598_2025_5033_Fig4_HTML.jpg

相似文献

1
Mortality and exacerbation risk according to GOLD and STAR severity stages of COPD: a 5-year multicenter prospective cohort study.慢性阻塞性肺疾病(COPD)根据GOLD和STAR严重程度分期的死亡率及急性加重风险:一项为期5年的多中心前瞻性队列研究
Sci Rep. 2025 May 30;15(1):19097. doi: 10.1038/s41598-025-05033-w.
2
Severity of Airflow Obstruction Based on FEV/FVC Versus FEV Percent Predicted in the General U.S. Population.基于 FEV/FVC 与 FEV 预计值百分比的美国一般人群气流阻塞严重程度。
Am J Respir Crit Care Med. 2024 Dec 1;210(11):1308-1316. doi: 10.1164/rccm.202310-1773OC.
3
Comparison of STAR and GOLD in Assessing Disease Severity Among High-Risk and COPD Patients: Evidence from Enjoying Breathing Program in China.STAR与GOLD在评估高危慢性阻塞性肺疾病(COPD)患者疾病严重程度中的比较:来自中国“畅享呼吸”项目的证据
Int J Chron Obstruct Pulmon Dis. 2024 Dec 27;19:2751-2762. doi: 10.2147/COPD.S492178. eCollection 2024.
4
FEV/FVC Severity Stages for Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病的 FEV/FVC 严重程度分期。
Am J Respir Crit Care Med. 2023 Sep 15;208(6):676-684. doi: 10.1164/rccm.202303-0450OC.
5
Prediction of severe exacerbations and mortality in COPD: the role of exacerbation history and inspiratory capacity/total lung capacity ratio.慢性阻塞性肺疾病(COPD)严重加重和死亡率的预测:加重病史及吸气容量/肺总量比值的作用
Int J Chron Obstruct Pulmon Dis. 2018 Apr 5;13:1105-1113. doi: 10.2147/COPD.S155848. eCollection 2018.
6
Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.在商业保险人群中,根据疾病严重程度分层的 COPD 患者的医疗资源利用和恶化率。
J Manag Care Spec Pharm. 2019 Feb;25(2):205-217. doi: 10.18553/jmcp.2019.25.2.205.
7
Comparison of stability of the GOLD and STAR lung function classification for chronic obstructive pulmonary disease.慢性阻塞性肺疾病的GOLD和STAR肺功能分类稳定性比较。
BMJ Open Respir Res. 2025 May 16;12(1):e002830. doi: 10.1136/bmjresp-2024-002830.
8
Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data.慢性阻塞性肺疾病病死率预测比较 GOLD 2007 及 2011 分期系统:一项个体患者资料的汇总分析。
Lancet Respir Med. 2015 Jun;3(6):443-50. doi: 10.1016/S2213-2600(15)00157-5. Epub 2015 May 17.
9
Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study.应用 2017 年新版全球慢性阻塞性肺疾病倡议分类标准预测慢性阻塞性肺疾病患者的死亡率:一项队列研究。
Lancet Respir Med. 2018 Mar;6(3):204-212. doi: 10.1016/S2213-2600(18)30002-X. Epub 2018 Jan 10.
10
Determining prognosis in acute exacerbation of COPD.慢性阻塞性肺疾病急性加重期的预后判定
Int J Chron Obstruct Pulmon Dis. 2017 Jan 31;12:467-475. doi: 10.2147/COPD.S122382. eCollection 2017.

本文引用的文献

1
Update of prognosis and characteristics of chronic obstructive pulmonary disease in a real-world setting: a 5-year follow-up analysis of a multi-institutional registry.真实环境下慢性阻塞性肺疾病预后和特征的更新:一项多机构注册研究的 5 年随访分析。
BMC Pulm Med. 2024 Nov 6;24(1):556. doi: 10.1186/s12890-024-03347-5.
2
The prevalence and mortality risks of PRISm and COPD in the United States from NHANES 2007-2012.美国 NHANES 2007-2012 年中 PRISm 和 COPD 的流行率和死亡率风险。
Respir Res. 2024 May 15;25(1):208. doi: 10.1186/s12931-024-02841-y.
3
Severity of Airflow Obstruction Based on FEV/FVC Versus FEV Percent Predicted in the General U.S. Population.
基于 FEV/FVC 与 FEV 预计值百分比的美国一般人群气流阻塞严重程度。
Am J Respir Crit Care Med. 2024 Dec 1;210(11):1308-1316. doi: 10.1164/rccm.202310-1773OC.
4
Comparison of Disease Severity Classifications of Chronic Obstructive Pulmonary Disease: GOLD vs. STAR in Clinical Practice.慢性阻塞性肺疾病疾病严重程度分类的比较:临床实践中全球慢性阻塞性肺疾病倡议(GOLD)与慢性阻塞性肺疾病评估测试(STAR)的对比
Diagnostics (Basel). 2024 Mar 19;14(6):646. doi: 10.3390/diagnostics14060646.
5
All-Cause Mortality of Staging of Airflow Obstruction by Ratio-categorized Patients with Chronic Obstructive Pulmonary Disease among the General Population.普通人群中按比例分类的慢性阻塞性肺疾病患者气流阻塞分期的全因死亡率
Am J Respir Crit Care Med. 2024 Dec 1;210(11):1374-1376. doi: 10.1164/rccm.202311-2144LE.
6
Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry.特发性肺纤维化(IPF)或非特发性间质性肺炎患者的生存和急性加重:前瞻性多机构患者登记的 5 年随访分析。
BMJ Open Respir Res. 2023 Nov;10(1). doi: 10.1136/bmjresp-2023-001864.
7
FEV/FVC Severity Stages for Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病的 FEV/FVC 严重程度分期。
Am J Respir Crit Care Med. 2023 Sep 15;208(6):676-684. doi: 10.1164/rccm.202303-0450OC.
8
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.慢性阻塞性肺疾病全球倡议组织2023年报告:《慢性阻塞性肺疾病全球倡议》执行摘要
Am J Respir Crit Care Med. 2023 Apr 1;207(7):819-837. doi: 10.1164/rccm.202301-0106PP.
9
Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO/DYNAGITO Trials.噻托溴铵/奥达特罗与噻托溴铵相比可降低多种 COPD 患者的恶化率:TONADO/DYNAGITO 试验的汇总分析。
Adv Ther. 2020 Oct;37(10):4266-4279. doi: 10.1007/s12325-020-01438-3. Epub 2020 Aug 10.
10
A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β-Agonist (LABA) Combinations in COPD.慢性阻塞性肺疾病(COPD)中长效毒蕈碱拮抗剂(LAMA)与长效β受体激动剂(LABA)联合使用的网络荟萃分析
Pulm Ther. 2017 Dec;3(2):297-316. doi: 10.1007/s41030-017-0048-0. Epub 2017 Aug 22.